poisar

Stocks · News reference

Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data

Vandana Singh

Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GPCR
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

    Novo Nordisk announced positive phase III STEP Young study results showing semaglutide reduced BMI in children aged 6-12 with obesity, with 40.4% no longer classified as obese after 68 weeks. However, the company faces mounting competitive pressure from Eli Lilly's superior weight-loss drugs and emerging biotech competitors in the GLP-1 obesity treatment market.

    NVOLLYVKTXGPCR